Regeneron and Roche Await Data On Potential COVID-19 Blockbuster

Early Signs Of Efficacy Expected In September

 
• By Andrew McConaghie

Results from COVID-19 antibody therapies from Regeneron and Lilly and several other developers are expected soon – but their window of opportunity could be short.

Antibodies
Monoclonal antibody therapies could mimic the body's own defenses against SARS-CoV-2 virus - but act faster, and help block infection

More from Business

More from Scrip